S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
These 5 Tech Stocks Have 10x Potential (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
These 5 Tech Stocks Have 10x Potential (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
These 5 Tech Stocks Have 10x Potential (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
These 5 Tech Stocks Have 10x Potential (Ad)pixel
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
NASDAQ:PTCT

PTC Therapeutics - PTCT Stock Forecast, Price & News

$42.06
+0.51 (+1.23%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$40.89
$42.43
50-Day Range
$34.44
$54.79
52-Week Range
$25.01
$55.58
Volume
500,482 shs
Average Volume
689,670 shs
Market Capitalization
$3.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.50

PTC Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
32.0% Upside
$55.50 Price Target
Short Interest
Bearish
6.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
1.13mentions of PTC Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$81,143 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.79) to ($4.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

519th out of 1,052 stocks

Pharmaceutical Preparations Industry

245th out of 514 stocks

PTCT stock logo

About PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Stock News Headlines

PTC Therapeutics (NASDAQ:PTCT) Lowered to "Hold" at StockNews.com
Expert Ratings for PTC Therapeutics
See More Headlines
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Company Calendar

Last Earnings
10/28/2021
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTCT
Employees
1,177
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.50
High Stock Price Forecast
$76.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+32.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-523,900,000.00
Pretax Margin
-77.00%

Debt

Sales & Book Value

Annual Sales
$538.59 million
Book Value
($3.16) per share

Miscellaneous

Free Float
67,569,000
Market Cap
$3.02 billion
Optionable
Optionable
Beta
0.47

Key Executives

  • Dr. Stuart W. Peltz Ph.D. (Age 62)
    Co-Founder, CEO & Exec. Director
    Comp: $1.64M
  • Dr. Allan Steven Jacobson Ph.D.Dr. Allan Steven Jacobson Ph.D. (Age 76)
    Co-Founder, Chairman of Scientific Advisory Board & Independent Director
    Comp: $142.5k
  • Ms. Emily Luisa HillMs. Emily Luisa Hill (Age 42)
    Chief Financial Officer
    Comp: $814.34k
  • Dr. Neil Almstead Ph.D. (Age 55)
    Chief Technical Operations Officer
    Comp: $810.82k
  • Mr. Mark Elliott BouldingMr. Mark Elliott Boulding (Age 61)
    Exec. VP & Chief Legal Officer
    Comp: $824.09k
  • Mr. Eric PauwelsMr. Eric Pauwels (Age 61)
    Chief Bus. Officer
    Comp: $810.47k
  • Dr. Matthew B. Klein F.A.C.S. (Age 50)
    FACS, M.D., M.S., MS, Chief Operating Officer
  • Ms. Christine Utter (Age 44)
    Sr. VP, Chief Accounting Officer & Head of People Services
  • Ms. Ellen Welch Ph.D.
    Chief Scientific Officer
  • Alex Kane
    Investor Relations Officer













PTCT Stock - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTCT shares.
View PTCT analyst ratings
or view top-rated stocks.

What is PTC Therapeutics' stock price forecast for 2023?

9 analysts have issued 12-month price targets for PTC Therapeutics' shares. Their PTCT share price forecasts range from $40.00 to $76.00. On average, they predict the company's stock price to reach $55.50 in the next year. This suggests a possible upside of 32.0% from the stock's current price.
View analysts price targets for PTCT
or view top-rated stocks among Wall Street analysts.

How have PTCT shares performed in 2022?

PTC Therapeutics' stock was trading at $39.83 on January 1st, 2022. Since then, PTCT stock has increased by 5.6% and is now trading at $42.06.
View the best growth stocks for 2022 here
.

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our PTCT earnings forecast
.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($1.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.78) by $0.11. The biopharmaceutical company had revenue of $139 million for the quarter, compared to the consensus estimate of $118.87 million. PTC Therapeutics had a negative trailing twelve-month return on equity of 983.21% and a negative net margin of 76.28%. The business's revenue was up 68.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.03) EPS.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $710.00 million-$750.00 million, compared to the consensus revenue estimate of $726.44 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.03%), RTW Investments LP (7.82%), Armistice Capital LLC (4.03%), State Street Corp (3.93%), Macquarie Group Ltd. (2.17%) and Price T Rowe Associates Inc. MD (2.04%). Insiders that own company stock include Allan Steven Jacobson, Christine Marie Utter, Dawn Svoronos, Emily Luisa Hill, Eric Pauwels, Marcio Souza, Mark Elliott Boulding, Matthew B Klein, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends
.

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $42.06.

How much money does PTC Therapeutics make?

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.02 billion and generates $538.59 million in revenue each year. The biopharmaceutical company earns $-523,900,000.00 in net income (profit) each year or ($7.47) on an earnings per share basis.

How many employees does PTC Therapeutics have?

The company employs 1,177 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.

This page (NASDAQ:PTCT) was last updated on 12/3/2022 by MarketBeat.com Staff